Patents by Inventor Nadya Tarasova
Nadya Tarasova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11167012Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.Type: GrantFiled: July 29, 2019Date of Patent: November 9, 2021Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
-
Publication number: 20190374608Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.Type: ApplicationFiled: July 29, 2019Publication date: December 12, 2019Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
-
Patent number: 10363286Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.Type: GrantFiled: June 30, 2017Date of Patent: July 30, 2019Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
-
Publication number: 20170304401Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.Type: ApplicationFiled: June 30, 2017Publication date: October 26, 2017Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
-
Publication number: 20130316957Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Patent number: 8546524Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: GrantFiled: May 14, 2012Date of Patent: October 1, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20120282196Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: May 14, 2012Publication date: November 8, 2012Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Patent number: 8198402Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: GrantFiled: October 30, 2007Date of Patent: June 12, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20100093625Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: October 30, 2007Publication date: April 15, 2010Applicant: The U.S.A., as represented by the Secretary, Dept. of Health and Human ServiceInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20050171014Abstract: A conjugate comprising a ligand, a linker, and a cytotoxic agent, in which the linker is FALA, VLALA, ALAL, ALALA, ChaLALA, ChaChaLAL, NalChaLAL or NalLALA; a composition thereof; a method of delivering a cytotoxic agent in a cell-specific manner; and a method of treating cancer in a mammal.Type: ApplicationFiled: February 27, 2003Publication date: August 4, 2005Applicant: Government of the United States of America, represented by the Secretary, Department of HealthInventors: Nadya Tarasova, Christopher Michejda, Marcin Dyba, Carolyn Cohran